JP7442824B2 - Ｓｌｃ２６ａ３阻害剤及びその使用 - Google Patents

Ｓｌｃ２６ａ３阻害剤及びその使用 Download PDF

Info

Publication number
JP7442824B2
JP7442824B2 JP2020559529A JP2020559529A JP7442824B2 JP 7442824 B2 JP7442824 B2 JP 7442824B2 JP 2020559529 A JP2020559529 A JP 2020559529A JP 2020559529 A JP2020559529 A JP 2020559529A JP 7442824 B2 JP7442824 B2 JP 7442824B2
Authority
JP
Japan
Prior art keywords
slc26a3
compound
constipation
oxalate
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020559529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522255A5 (enExample
JP2021522255A (ja
Inventor
バークマン，アラン・エス
シル，オヌアー
ハギー，ピーター・エム
Original Assignee
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア filed Critical ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
Publication of JP2021522255A publication Critical patent/JP2021522255A/ja
Publication of JP2021522255A5 publication Critical patent/JP2021522255A5/ja
Application granted granted Critical
Publication of JP7442824B2 publication Critical patent/JP7442824B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020559529A 2018-04-25 2019-04-25 Ｓｌｃ２６ａ３阻害剤及びその使用 Active JP7442824B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662574P 2018-04-25 2018-04-25
US62/662,574 2018-04-25
PCT/US2019/029219 WO2019210103A2 (en) 2018-04-25 2019-04-25 Slc26a3 inhibitors and use thereof

Publications (3)

Publication Number Publication Date
JP2021522255A JP2021522255A (ja) 2021-08-30
JP2021522255A5 JP2021522255A5 (enExample) 2022-05-09
JP7442824B2 true JP7442824B2 (ja) 2024-03-05

Family

ID=67439317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559529A Active JP7442824B2 (ja) 2018-04-25 2019-04-25 Ｓｌｃ２６ａ３阻害剤及びその使用

Country Status (6)

Country Link
US (2) US11591304B2 (enExample)
EP (1) EP3784229A2 (enExample)
JP (1) JP7442824B2 (enExample)
AU (1) AU2019257722B2 (enExample)
CA (1) CA3098293A1 (enExample)
WO (1) WO2019210103A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019005196A1 (de) * 2019-07-25 2021-01-28 Forschungszentrum Jülich GmbH Verfahren zur Herstellung eines Cumarin-caged Forskolinderivats, Forskolinderivat und Verwendung des Forskolinderivats
US20250073242A1 (en) 2021-07-30 2025-03-06 The Regents Of The University Of California Slc26a3 inhibitors and use thereof
WO2023081967A1 (en) * 2021-11-10 2023-05-19 The University Of Western Australia Compounds and uses therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101362722B (zh) * 2008-09-27 2011-04-27 山东大学 N-取代苯基-2-(1-芳基-1h-咪唑-2-巯基)乙酰胺类衍生物及其制备方法与应用
WO2010056914A1 (en) 2008-11-12 2010-05-20 Microbiotix, Inc. Bacterial helicase inhibitor compounds and uses thereof
WO2017147523A1 (en) 2016-02-26 2017-08-31 The Regents Of The University Of California Small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Am J Physiol Gastrointest Liver Physiol，2013年，Vol.305，pp.G520-G527
Database REGISTRY，2003年，RN 500203-66-7，Retrieved from STN international [online] ;retrieved on 27 March 2023
Database REGISTRY，2003年，RN 500203-86-1，Retrieved from STN international [online] ;retrieved on 27 March 2023
Database REGISTRY，2004年，RN 701923-88-8，Retrieved from STN international [online] ;retrieved on 27 March 2023
Database REGISTRY，2005年，RN 858743-95-0，Retrieved from STN international [online] ;retrieved on 27 March 2023
JCI Insight，2018年，Vol.3, No.14，e121370 (pp.1-13)，Supplemental data (pp.1-12)

Also Published As

Publication number Publication date
AU2019257722B2 (en) 2025-04-03
US12187694B2 (en) 2025-01-07
JP2021522255A (ja) 2021-08-30
US20230339878A1 (en) 2023-10-26
US11591304B2 (en) 2023-02-28
US20210363123A1 (en) 2021-11-25
EP3784229A2 (en) 2021-03-03
WO2019210103A3 (en) 2020-01-16
AU2019257722A1 (en) 2020-11-19
CA3098293A1 (en) 2019-10-31
WO2019210103A2 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US12187694B2 (en) SLC26A3 inhibitors and use thereof
CN113717157B (zh) 用作cdk7激酶抑制剂的化合物及其应用
EP2148865B1 (en) Pyrazole inhibitors of wnt signaling
RU2584986C2 (ru) Агонисты протеинтирозинфосфатазы-1, содержащей домен гомологии-2 src, и способы лечения с применением указанных агонистов
EA025033B1 (ru) Диаминиевые соли фенотиазина и их применение
KR20170117170A (ko) 위 배출을 감소시키기 위한 방법 및 조성물
CN102766103B (zh) 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
CN108366997A (zh) 治疗痛觉过敏的方法
WO2019173482A1 (en) 4-aminoquinoline compounds for the treatment of angiogenesis
JP2007525494A6 (ja) ヘパラナーゼ阻害剤及びその使用
JP2007525494A (ja) ヘパラナーゼ阻害剤及びその使用
WO2021013084A1 (zh) 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
JP5153621B2 (ja) Ｓｈｐ−２阻害剤、それらを含む薬剤組成物及びホスファターゼ媒介性疾患を治療するためのその使用
US12503447B2 (en) CFTR regulators and methods of use thereof
US6255298B1 (en) Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
CN112107568A (zh) 二芳基酰胺类化合物及其应用
WO2000003704A1 (en) Macrophage scavenger receptor antagonists
WO2026002133A1 (zh) 一种蛋白酪氨酸激酶抑制剂的盐型
HK40104383A (en) Compounds and compositions for treating hematological disorders
CN119654310A (zh) 用于治疗胃肠和肺疾病的作为前列腺素e2受体4（ep4）激动剂的1,2-取代的3-氧代吡唑烷衍生物
HK40031549B (en) Compounds and compositions for treating hematological disorders
HK1139666B (en) Modulators of cystic fibrosis transmembrane conductance regulator
HK1139666A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
JP2009007290A (ja) フェニルプロペンアミド誘導体を有効成分とする糖化最終産物形成阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7442824

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150